A Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Participants (Part I), and After Multiple Dose Regimens in Participants With Chronic Hepatitis B (Part II)

NCT02662712 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

87

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy
Hepatitis, Chronic

Interventions

DRUG: JNJ-56136379
DRUG: Placebo

Sponsor

Janssen Sciences Ireland UC